Participants had a mean age of 55.1 years (SD = 14), were predominantly female, and primarily cared for a parent. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
32/100
Dementia is the waning of cognitive abilities, which is typically seen with the natural aging process and includes issues with memory, language, and problem-solving abilities. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The 2024 Lancet Commission estimates 45% of dementias worldwide are preventable if 14 potentially modifiable risk factors for dementia were eliminated. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Participation in late-life cognitive activities has been associated with a slower rate of cognitive decline and reduced risk of dementia; however, whether this association is independent of earlier experiences is unclear. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Instrumental assessments (Videofluoroscopic Swallowing Study [VFSS], Fiberoptic Endoscopic Evaluation of Swallowing [FEES]) and the Water Swallow Test were most frequently used.ICF mapping revealed that 96.7% of tools focused on body functions, while only approximately 20% addressed participation and environmental factors. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We created and hosted a dementia workshop for first and second year medical students in 2023 and 2024 aimed at increasing interest and passion for empathic dementia care. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We sought to identify patterns in occupational therapy (OT) and physical therapy (PT) home health care visits among people living with dementia (PLWD) by (1) level of function care partner report compared with administrative data, (2) race and ethnicity, and (3) level of socioeconomic resources. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
32/100
SSP is a flexible and predictive neighborhood‐level measure of health disparities compared to indices like the Gini coefficient. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Frontotemporal dementia (FTD) is one of the most common forms of dementia in persons younger than 65 years. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The translated Adaptation-Coping (adjusting to change) Model provides a way for service users (people with dementia and families) to conceptualise their journey with dementia post-diagnosis, and potentially provides service providers and researchers with aims for treatment and support. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Using multiple Medicare Public Use Files (PUF), including star ratings for home health quality of patient care (QoPC), home health care CAHPS survey (HHCAHPS), county-level ADRD prevalence, and Medicare FFS enrollment, we found that the median county-level number of home health agencies was 15 (IQR 8-29), star rating was 3.4 (IQR 3.1-3.7) for QoPC and 3.8 (IQR 3.5-4.0) for HHCAHPS. 2 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
ADRD specialist and drug utilization is relatively low in both DS and non‐DS, with no significant R/E differences. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
31/100
An estimated two thirds of people living with Alzheimer’s disease or related dementias (ADRD) live and are cared for at home. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
LUMEN demonstrated strong performance in distinguishing dementia from normal cognition (AUROC=0.89) but moderate subtype differentiation (AUROC=0.66). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Across the literature, it is evident that health inequalities currently exist and exacerbate the disparities in the care of BAME dementia patients. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia is a progressive neurodegenerative disorder that represents a growing challenge to global health, especially in aging populations. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In last two decades the growing life expectancy has spiralled the prevalence of neurogenerative disorder such as Dementia among elderly population posing a significant challenge to mental health globally. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
These findings suggest that participatory art, when integrated into community activities, can be a valuable resource for people with dementia and MCI, fostering social participation and self-expression. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The YOD group was more cognitively compromised, more anxious, and presented more aberrant motor behaviors than the LOD group. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The Healthy Brain Initiative: The Public Health Road Map for State and National Partnerships was recently updated for years 2018-2022, which includes recommendations for implementing emergency preparedness (EP) measures at the state and local levels with attention to the unique needs of people living with Alzheimer's disease and other related dementias (ADRD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia risk is influenced by biological and lifestyle factors as well as broader socioeconomic conditions; however, the extent to which socioeconomic deprivation creates structural exposures that affect cognitive aging remains unclear. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Of 6,911,104 patients (min=Idaho: 45,160; max=California: 2.46 million), we observed a substantial difference in overall diagnosed prevalence across states of residence: Oregon and Montana had the highest diagnosed prevalence (6.6% and 6.5%, respectively); New Mexico had the lowest (2.3%). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Geographical differences in Alzheimer’s disease and related dementias (ADRD) prevalence may be driven by under-diagnosis due to insufficient healthcare access. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
ADRD mortality rates were slightly higher in rural areas compared to urban areas, with no significant differences between rural-adjacent and rural-nonadjacent counties in recent years. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The FFMQ-15 may reflect different experiences of mindfulness among Black caregivers of PWD. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
From across this tag
10 of the 1,233 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Different cognitive profiles for single compared with recurrent fallers without dementia
- A longitudinal study of language decline in Alzheimer's disease and frontotemporal dementia
- Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: a systematic review
- Treatment patterns and burden of behavioral disturbances in patients with dementia in the United States: a claims database analysis
- Multicentre population-based dementia prevalence survey in Japan: a preliminary report
- Clinical Presentation of COVID19 in Dementia Patients
- Prevalence and treatment of neuropsychiatric symptoms in advanced dementia
- Do Older Mexican Americans With Dementia Benefit From Living Closer to the Border? Evidence From the HEPESE
- Predicting incident dementia 3-8 years after brief cognitive tests in the UK Biobank prospective study of 500,000 people
- Mixed brain pathologies account for most dementia cases in community-dwelling older persons
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →